COMPARISON OF THE KINETIC INTERACTIONS OF THE NEUROLEPTICS PERPHENAZINE AND ZUCLOPENTHIXOL WITH TRICYCLIC ANTIDEPRESSIVES

被引:10
作者
LINNET, K
机构
[1] Institute for Basic Research in Psychiatry, Clinical Biochemical Laboratory, Psychiatric Hospital in Aarhus, Risskov
关键词
DRUG INTERACTIONS; ZUCLOPENTHIXOL; ANTIDEPRESSIVES;
D O I
10.1097/00007691-199506000-00016
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Using data from a therapeutic drug monitoring database, kinetic interactions between the neuroleptics zuclopenthixol and perphenazine and tricyclic antidepressives were studied. Out of 290 patients monitored for amitriptyline and 611 patients monitored for nortriptyline, 77 patients were comedicated with perphenazine and 50 patients with zuclopenthixol. Comedication with perphenazine increased the median steady-state serum concentration to daily dose ratio (CID) of nortriptyline by 30-45%, whereas the median CID of amitriptyline was unaffected. On the contrary, median CID values of nortriptyline and amitriptyline were not significantly influenced by comedication with zuclopenthixol. Thus, in accordance with previous studies, perphenazine increases the concentration of tricyclic antidepressives to a moderate extent. Zuclopenthixol, on the other hand, does not exert any impact under routine therapeutic drug monitoring, even though the drug is known to partly depend on metabolism by the isozyme cytochrome P450 2D6.
引用
收藏
页码:308 / 311
页数:4
相关论文
共 22 条
[1]   IMPAIRMENT OF HEPATIC DRUG OXIDATION BY PROPOXYPHENE [J].
ABERNETHY, DR ;
GREENBLATT, DJ ;
STEEL, K ;
SHADER, RI .
ANNALS OF INTERNAL MEDICINE, 1982, 97 (02) :223-224
[2]   IMPORTANCE OF OXIDATIVE POLYMORPHISM AND LEVOMEPROMAZINE TREATMENT ON THE STEADY-STATE BLOOD-CONCENTRATIONS OF CLOMIPRAMINE AND ITS MAJOR METABOLITES [J].
BALANTGORGIA, AE ;
BALANT, LP ;
GENET, C ;
DAYER, P ;
AESCHLIMANN, JM ;
GARRONE, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (04) :449-455
[3]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[4]  
BROSEN K, 1993, NORD J PSYCHIATR S30, V47, P21
[5]  
CIRAULO DA, 1985, AM J PSYCHIAT, V142, P1373
[6]  
Conover W.J., 1999, PRACTICAL NONPARAMET, P428, DOI DOI 10.1002/BIMJ.19730150311
[7]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[8]   DISPOSITION OF THE NEUROLEPTIC ZUCLOPENTHIXOL COSEGREGATES WITH THE POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN HUMANS [J].
DAHL, ML ;
EKQVIST, B ;
WIDEN, J ;
BERTILSSON, L .
ACTA PSYCHIATRICA SCANDINAVICA, 1991, 84 (01) :99-100
[9]   DRUG INTERACTION - INHIBITORY EFFECT OF NEUROLEPTICS ON METABOLISM OF TRICYCLIC ANTIDEPRESSANTS IN MAN [J].
GRAM, LF ;
OVERO, KF .
BRITISH MEDICAL JOURNAL, 1972, 1 (5798) :463-&
[10]  
GRAM LF, 1974, ACTA PHARMACOL TOX, V35, P223